Characteristics and Prognostic Analysis of 69 Patients With Pulmonary Sarcomatoid Carcinoma.

Abstract

BACKGROUND:

Pulmonary sarcomatoid carcinoma (PSC) is a rare malignancy.

METHODS:

A total of 69 patients with PSC treated at a single institution in southern China with long-term follow-up were evaluated in this study. We analyzed the clinical characteristics, immunohistochemical profiles, epidermal growth factor receptor mutation status, K-RAS mutation status, treatments, and prognosis.

RESULTS:

PSC mainly occurred in young male patients with a history of smoking. Most patients received multimodality treatments and the majority had early-stage disease. The median survival time was 19.1 months, and the 5-year survival rate was 17.4%. The patients without distant metastasis, with normal or higher body mass index (≥18.5), with normal hemoglobin, with smaller tumor size (≤4 cm), and those who received complete resection had significantly better overall survival (P<0.05). The patients with pleomorphic carcinoma had much worse prognosis. In a Cox regression model, M stage, pathology, and having received a complete resection were independent prognostic factors (P<0.05).

CONCLUSIONS:

PSC is a unique lung malignancy with poor prognosis. Patients receiving complete resection had better prognosis, likely a reflection of early-stage disease. Neither neoadjuvant nor adjuvant chemotherapy improved patient survival for those with early-stage disease. The retrospective design and small sample size limited the generalizability. Future multicenter collaborations may be necessary to determine the optimal treatment.

• Authors: Yongbin Lin, Han Yang, Qingqing Cai, Daofeng Wang, Huilan Rao, Suxia Lin, Hao Long, Jianhua Fu, Lanjun Zhang, Peng Lin, Guangchuan Xu, Tiehua Rong, Xiaoxing Xiong, Guowei Ma, Ying Liang
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 39 Issue 3 Pg. 215-22 (06 2016) ISSN: 1537-453X [Electronic] United States
• PMID: 25068469 (Publication Type: Journal Article)

Chemical References

• KRAS protein, human
• Mucin-1
• Nuclear Proteins
• S100 Proteins
• Thyroid Nuclear Factor 1
• Transcription Factors
• Vimentin
• Keratins
• EGFR protein, human
• ErbB Receptors
• Proto-Oncogene Proteins p21(ras)

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Carcinoma (chemistry, pathology, secondary, therapy)
• Carcinoma, Giant Cell (chemistry, secondary, therapy)
• Carcinosarcoma (chemistry, secondary, therapy)
• Combined Modality Therapy
• Disease-Free Survival
• ErbB Receptors (genetics)
• Female
• Follow-Up Studies
• Humans
• Keratins (analysis)
• Lung Neoplasms (chemistry, pathology, therapy)
• Male
• Middle Aged
• Mucin-1 (analysis)
• Nuclear Proteins (analysis)
• Prognosis
• Proto-Oncogene Proteins p21(ras) (genetics)
• Pulmonary Blastoma (chemistry, secondary, therapy)
• S100 Proteins (analysis)
• Survival Rate
• Thyroid Nuclear Factor 1
• Transcription Factors (analysis)
• Vimentin (analysis)
• Young Adult